ATE243026T1 - Bupropion-darreichungsform mit kontrollierter freisetzung - Google Patents

Bupropion-darreichungsform mit kontrollierter freisetzung

Info

Publication number: ATE243026T1
Authority: AT; Austria
Prior art keywords: dosage form; controlled release; bupropion; release dosage; coating
Prior art date: 1999-02-26

Application number

AT00908780T

Other languages

English (en)

Inventor

Chih-Ming Chen

Jianbo Xie

Steve Jan

Original Assignee

Andrx Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-02-26

Filing date

2000-02-24

Publication date

2003-07-15

2000-02-24 Application filed by Andrx Pharmaceuticals Inc filed Critical Andrx Pharmaceuticals Inc

2003-07-15 Application granted granted Critical

2003-07-15 Publication of ATE243026T1 publication Critical patent/ATE243026T1/de

Links

238000013270 controlled release Methods 0.000 title abstract 2
239000002552 dosage form Substances 0.000 title abstract 2
SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 title 1
229960001058 bupropion Drugs 0.000 title 1
IKBZAUYPBWFMDI-UHFFFAOYSA-N 5-bromo-4-methoxy-7-methyl-2,3-dihydro-1h-indene Chemical compound C1=C(Br)C(OC)=C2CCCC2=C1C IKBZAUYPBWFMDI-UHFFFAOYSA-N 0.000 abstract 3
229960004367 bupropion hydrochloride Drugs 0.000 abstract 3
239000011248 coating agent Substances 0.000 abstract 3
238000000576 coating method Methods 0.000 abstract 3
239000004925 Acrylic resin Substances 0.000 abstract 2
229920000178 Acrylic resin Polymers 0.000 abstract 2
230000002378 acidificating effect Effects 0.000 abstract 2
239000001866 hydroxypropyl methyl cellulose Substances 0.000 abstract 2
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 abstract 2
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 abstract 2
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 abstract 2
239000000203 mixture Substances 0.000 abstract 2
239000008188 pellet Substances 0.000 abstract 2
239000001856 Ethyl cellulose Substances 0.000 abstract 1
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 abstract 1
229920001688 coating polymer Polymers 0.000 abstract 1
239000002702 enteric coating Substances 0.000 abstract 1
238000009505 enteric coating Methods 0.000 abstract 1
229920001249 ethyl cellulose Polymers 0.000 abstract 1
235000019325 ethyl cellulose Nutrition 0.000 abstract 1
229920003176 water-insoluble polymer Polymers 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs

Landscapes

Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

AT00908780T 1999-02-26 2000-02-24 Bupropion-darreichungsform mit kontrollierter freisetzung ATE243026T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US09/259,133 US6210716B1 (en)	1999-02-26	1999-02-26	Controlled release bupropion formulation
PCT/US2000/004636 WO2000050010A1 (en)	1999-02-26	2000-02-24	Controlled release bupropion formulation

Publications (1)

Publication Number	Publication Date
ATE243026T1 true ATE243026T1 (de)	2003-07-15

Family

ID=22983669

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT00908780T ATE243026T1 (de)	1999-02-26	2000-02-24	Bupropion-darreichungsform mit kontrollierter freisetzung

Country Status (10)

Country	Link
US (1)	US6210716B1 (de)
EP (1)	EP1162951B1 (de)
JP (1)	JP2002537319A (de)
AT (1)	ATE243026T1 (de)
AU (1)	AU757915B2 (de)
CA (1)	CA2363168A1 (de)
DE (1)	DE60003396T2 (de)
ES (1)	ES2200832T3 (de)
HK (1)	HK1043051B (de)
WO (1)	WO2000050010A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8545880B2 (en) *	1999-02-26	2013-10-01	Andrx Pharmaceuticals, Llc	Controlled release oral dosage form
AU2001247887A1 (en) *	2000-04-19	2001-11-07	Eurand America Inc.	Dual mechanism timed release dosage forms for low dose drugs
AU2001230490A1 (en) *	2000-12-01	2002-06-11	Arun Shriniwas Gosavi	Pharmaceutical formulation
WO2002062299A2 (en) *	2001-02-08	2002-08-15	Andrx Pharmaceuticals, Inc.	Improved controlled release oral dosage form
ITMI20011457A1 (it) *	2001-07-09	2003-01-09	Valpharma Sa	Composizione farmaceutica a rilascio modificato contenente bupropionehc1 come sostanza attiva
MXPA04011203A (es) *	2002-05-17	2005-07-14	Univ Duke	Metodo para tratar la obesidad.
US20050215552A1 (en) *	2002-05-17	2005-09-29	Gadde Kishore M	Method for treating obesity
US6893660B2 (en) *	2002-11-21	2005-05-17	Andrx Pharmaceuticals, Inc.	Stable pharmaceutical compositions without a stabilizer
US20040131672A1 (en) *	2003-01-07	2004-07-08	Nilobon Podhipleux	Direct compression pharmaceutical composition containing a pharmaceutically active ingredient with poor flowing properties
WO2004096201A1 (en) *	2003-04-29	2004-11-11	Orexigen Therapeutics, Inc.	Compositions for affecting weight loss
US7632521B2 (en) *	2003-07-15	2009-12-15	Eurand, Inc.	Controlled release potassium chloride tablets
KR101087464B1 (ko) *	2003-08-08	2011-11-25	밸리언트 인터내셔널(바베이도스) 에스알엘	부프로피온 히드로클로라이드의 개질 방출형 정제
EP1734955A2 (de) *	2004-01-13	2006-12-27	Duke University	Zusammensetzungen eines antikonvulsiven mittels und eines antipsychotischen mittels zur beeinflussung des gewichtsverlustes
US7713959B2 (en) *	2004-01-13	2010-05-11	Duke University	Compositions of an anticonvulsant and mirtazapine to prevent weight gain
EP1748776A1 (de) *	2004-05-03	2007-02-07	Duke University	Zusammensetzungen zur beeinflussung des gewichtsverlusts
US8586085B2 (en) *	2004-11-08	2013-11-19	Biokey, Inc.	Methods and formulations for making pharmaceutical compositions containing bupropion
US20060099261A1 (en) *	2004-11-08	2006-05-11	Biokey, Inc.	Methods and formulations for making controlled release oral dosage form
US20060099262A1 (en) *	2004-11-08	2006-05-11	Biokey, Inc.	Methods and formulations for making controlled release oral dosage form
KR100670798B1 (ko)	2004-12-17	2007-01-17	한국전자통신연구원	데이터베이스 캐시 시스템
RU2408368C2 (ru) *	2005-06-27	2011-01-10	Биовэйл Лэборэториз Интернэшнл С.Р.Л.	Препараты соли бупропиона с модифицированным высвобождением
ES2761812T3 (es) *	2005-11-22	2020-05-21	Nalpropion Pharmaceuticals Inc	Composición y métodos de aumento de la sensibilidad a la insulina
PL1954241T3 (pl) *	2005-11-28	2013-03-29	Orexigen Therapeutics Inc	Formulacja zonisamidu o przedłużonym uwalnianiu
WO2007117314A2 (en) *	2005-12-06	2007-10-18	Biokey, Inc.	Bupropion controlled release formulations and methods of making
US8916195B2 (en)	2006-06-05	2014-12-23	Orexigen Therapeutics, Inc.	Sustained release formulation of naltrexone
DK2089005T3 (da)	2006-11-09	2010-07-19	Orexigen Therapeutics Inc	Lagdelte farmaceutiske formuleringer omfattende et hurtigt opløsende mellemlag
KR20150082689A (ko)	2006-11-09	2015-07-15	오렉시젠 세러퓨틱스 인크.	단위 용량 팩키지
WO2008129501A2 (en) *	2007-04-20	2008-10-30	Wockhardt Research Centre	Pharmaceutical compositions of duloxetine
WO2009158114A1 (en)	2008-05-30	2009-12-30	Orexigen Therapeutics, Inc.	Methods for treating visceral fat conditions
US20100239681A1 (en) *	2009-03-20	2010-09-23	Biokey, Inc.	Controlled Release Particulates Containing Water-Insoluble Drug
CN102724878A (zh) *	2010-01-11	2012-10-10	奥雷西根治疗公司	在重度抑郁症患者中提供体重减轻疗法的方法
HUE072188T2 (hu)	2012-06-06	2025-10-28	Nalpropion Pharmaceuticals Llc	Készítmény magas kardiovaszkuláris kockázatú túlsúlyos és elhízott páciensek kezelésére szolgáló eljárásban történõ alkalmazásra
JP6392355B2 (ja)	2013-09-13	2018-09-19	アール．ピー．シェーラーテクノロジーズ、エルエルシー	ペレット包含錠剤
US8969371B1 (en)	2013-12-06	2015-03-03	Orexigen Therapeutics, Inc.	Compositions and methods for weight loss in at risk patient populations

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2011587A (en)	1934-03-24	1935-08-20	Kelp Ol Lab Inc	Coating for medical compound
US2987445A (en)	1958-10-10	1961-06-06	Rohm & Haas	Drug composition
GB906331A (en)	1959-12-21	1962-09-19	Kefalas As	Appetite-reducing compositions comprising phenylamino propane derivatives
GB972128A (en)	1960-01-21	1964-10-07	Wellcome Found	Pellets for supplying biologically active substances to ruminants and the manufacture of such pellets
US4060598A (en)	1967-06-28	1977-11-29	Boehringer Mannheim G.M.B.H.	Tablets coated with aqueous resin dispersions
US3538214A (en)	1969-04-22	1970-11-03	Merck & Co Inc	Controlled release medicinal tablets
BE759838A (fr)	1969-12-04	1971-06-03	Wellcome Found	Cetones a activite biologique
US3885046A (en)	1969-12-04	1975-05-20	Burroughs Wellcome Co	Meta chloro or fluoro substituted alpha-T-butylaminopropionphenones in the treatment of depression
US3773920A (en)	1971-07-14	1973-11-20	Nikken Chemicals Co Ltd	Sustained release medicinal composition
US4093708A (en)	1974-12-23	1978-06-06	Alza Corporation	Osmotic releasing device having a plurality of release rate patterns
US4014334A (en)	1976-02-02	1977-03-29	Alza Corporation	Laminated osmotic system for dispensing beneficial agent
US4016880A (en)	1976-03-04	1977-04-12	Alza Corporation	Osmotically driven active agent dispenser
US4256108A (en)	1977-04-07	1981-03-17	Alza Corporation	Microporous-semipermeable laminated osmotic system
US4309405A (en)	1979-08-09	1982-01-05	American Home Products Corporation	Sustained release pharmaceutical compositions
CH647150A5 (de)	1980-01-21	1985-01-15	Wellcome Found	Zubereitung, enthaltend ein tranquillans und ein propiophenon.
US4327725A (en)	1980-11-25	1982-05-04	Alza Corporation	Osmotic device with hydrogel driving member
US4439194A (en)	1981-09-08	1984-03-27	Merck & Co., Inc.	Water and drug delivery system for suppository use
US4393078A (en)	1982-03-15	1983-07-12	Burroughs Wellcome Co.	Bupropion and ethanol
US4439196A (en)	1982-03-18	1984-03-27	Merck & Co., Inc.	Osmotic drug delivery system
US4557925A (en)	1982-07-08	1985-12-10	Ab Ferrosan	Membrane-coated sustained-release tablets and method
US4519801A (en)	1982-07-12	1985-05-28	Alza Corporation	Osmotic device with wall comprising cellulose ether and permeability enhancer
DK58983D0 (da) *	1983-02-11	1983-02-11	Leo Pharm Prod Ltd	Farmaceutisk praeparat
US4539198A (en)	1983-07-07	1985-09-03	Rowell Laboratories, Inc.	Solid pharmaceutical formulations for slow, zero order release via controlled surface erosion: expanded range
USRE33994E (en)	1983-08-16	1992-07-14	Burroughs Wellcome Co.	Pharmaceutical delivery system
US4507323A (en)	1984-07-25	1985-03-26	Burroughs Wellcome Co.	Treatment of psychosexual dysfunctions
US4769027A (en)	1984-08-15	1988-09-06	Burroughs Wellcome Co.	Delivery system
US4935429A (en)	1985-10-25	1990-06-19	Dackis Charles A	Method of treating psychostimulant addiction
GB2189699A (en) *	1986-04-30	1987-11-04	Haessle Ab	Coated acid-labile medicaments
JPH07552B2 (ja) *	1987-11-06	1995-01-11	田辺製薬株式会社	持効性製剤
DE3812799A1 (de) *	1988-04-16	1989-10-26	Sanol Arznei Schwarz Gmbh	Oral zu verabreichende pharmazeutische zubereitung mit kontrollierter wirkstofffreisetzung und verfahren zu deren herstellung
DE3822095A1 (de) *	1988-06-30	1990-01-04	Klinge Co Chem Pharm Fab	Neue arzneimittelformulierung sowie verfahren zu deren herstellung
IT1230576B (it) *	1988-10-20	1991-10-28	Angeli Inst Spa	Formulazioni farmaceutiche per via orale a liberazione selettiva nel colon
CA2002492A1 (en)	1988-11-11	1990-05-11	Sandra T. A. Malkowska	Pharmaceutical ion exchange resin composition
US5098715A (en)	1990-12-20	1992-03-24	Burroughs Wellcome Co.	Flavored film-coated tablet
US5260068A (en) *	1992-05-04	1993-11-09	Anda Sr Pharmaceuticals Inc.	Multiparticulate pulsatile drug delivery system
GB9217295D0 (en) *	1992-08-14	1992-09-30	Wellcome Found	Controlled released tablets
US5260069A (en) *	1992-11-27	1993-11-09	Anda Sr Pharmaceuticals Inc.	Pulsatile particles drug delivery system
GB9315856D0 (en)	1993-07-30	1993-09-15	Wellcome Found	Stabilized pharmaceutical
US5541231A (en)	1993-07-30	1996-07-30	Glaxo Wellcome Inc.	Stabilized Pharmaceutical
US5358970A (en)	1993-08-12	1994-10-25	Burroughs Wellcome Co.	Pharmaceutical composition containing bupropion hydrochloride and a stabilizer

1999
- 1999-02-26 US US09/259,133 patent/US6210716B1/en not_active Expired - Fee Related
2000
- 2000-02-24 WO PCT/US2000/004636 patent/WO2000050010A1/en not_active Ceased
- 2000-02-24 AU AU30058/00A patent/AU757915B2/en not_active Ceased
- 2000-02-24 EP EP00908780A patent/EP1162951B1/de not_active Expired - Lifetime
- 2000-02-24 DE DE60003396T patent/DE60003396T2/de not_active Expired - Fee Related
- 2000-02-24 JP JP2000600622A patent/JP2002537319A/ja active Pending
- 2000-02-24 CA CA002363168A patent/CA2363168A1/en not_active Abandoned
- 2000-02-24 ES ES00908780T patent/ES2200832T3/es not_active Expired - Lifetime
- 2000-02-24 HK HK02104353.1A patent/HK1043051B/en not_active IP Right Cessation
- 2000-02-24 AT AT00908780T patent/ATE243026T1/de not_active IP Right Cessation

Also Published As

Publication number	Publication date
HK1043051A1 (en)	2002-09-06
HK1043051B (en)	2004-02-06
WO2000050010A1 (en)	2000-08-31
EP1162951A4 (de)	2002-09-04
AU757915B2 (en)	2003-03-13
AU3005800A (en)	2000-09-14
EP1162951B1 (de)	2003-06-18
CA2363168A1 (en)	2000-08-31
EP1162951A1 (de)	2001-12-19
ES2200832T3 (es)	2004-03-16
US6210716B1 (en)	2001-04-03
JP2002537319A (ja)	2002-11-05
DE60003396D1 (de)	2003-07-24
DE60003396T2 (de)	2004-04-22

Legal Events

Date	Code	Title	Description
2003-12-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE60003396D1 (de)	2003-07-24	Bupropion-darreichungsform mit kontrollierter freisetzung
PL356962A1 (en)	2004-07-12	Multi-particulate form of medicament, comprising at least two differently coated forms of pellet
ATE287260T1 (de)	2005-02-15	Formulierung mit einer vorgeformten öffnung zur gesteuerten freisetzung
DE60036874D1 (de)	2007-12-06	Pellet formulierung mit gesteuerter freisetzung
DK1191926T3 (da)	2005-06-13	Ny omeprazol- og (S)-omeprazolformulering
CA2351814A1 (en)	2001-12-30	Taste masked pharmaceutical particles
DK0977557T3 (da)	2003-09-15	Pelletpræparat til behandling af tarmkanalen
CA2046739A1 (en)	1992-01-11	Coated solid medicament form having releasability in large intestine
ATE432065T1 (de)	2009-06-15	Gelbeschichtete zusammensetzungen mit verzögerter freisetzung
BG101901A (bg)	1998-10-30	2-метил-тиено-бензодиазепинова формулировка за приемане през устата и метод за нейното получаване
NO20052860L (no)	2005-08-10	Farmasoytiske pelletter omfattende tamsulosin og en fremgangsmate for fremstilling av samme
GB9025372D0 (en)	1991-01-09	Pharmaceutical dosage forms
SE9704869D0 (sv)	1997-12-22	New pharmaceutical formulaton II
DE69721845D1 (de)	2003-06-12	Orale morphinzubereitung in teilchenform
KR960003722A (ko)	1996-02-23	장용성 듀로세틴 펠릿
NZ511448A (en)	2003-06-30	A dosage form of diltiazem that exhibits a release rate profile corresponding to a "two peak" plasma level profile in vivo
BG105061A (bg)	2001-07-31	Ентерично покрит фармацевтичен състав и метод за получаване
NZ509028A (en)	2002-12-20	Stable extended release oral dosage composition comprising a pseudoephedrine-containing core, the core being uniformly covered with a desloratadine-containing film
ATE244002T1 (de)	2003-07-15	Pharmazeutische formulierung mit omeprazol
WO2002024174A3 (en)	2002-09-26	Sustained release composition containing clarithromycin
ATE391496T1 (de)	2008-04-15	Geschmacksmaskierte pharmazeutische formulierungen
ES2104044T3 (es)	1997-10-01	Capsulas blandas revestidas entericas y metodo para su produccion.
NZ527585A (en)	2005-04-29	Tablets quickly disintegrated in oral cavity
BR9711378A (pt)	1999-08-17	Forma gal-ncia com libera-Æo prolongada
ES8802115A1 (es)	1988-04-01	Procedimiento para la preparacion de formas de administracion de medicamentos solidas y duraderas a base de hidroxipropilcelulosa.